Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study
The findings emphasize the potential of Eribulin in the treatment of HER2-negative advanced breast cancer, highlighting the need for further large-scale, prospective studies to refine and enhance treatment strategies.
Authors
- Ting Hu (ORCID: https://orcid.org/0000-0003-4720-1742)
- Yuting Li (ORCID: https://orcid.org/0000-0003-4407-8662)
- Jie Xiong (ORCID: https://orcid.org/0000-0002-6350-5853)
- Yuehua Wang (ORCID: https://orcid.org/0000-0002-7650-6417)
- Yanxia Zhao (ORCID: https://orcid.org/0009-0000-6399-6464)
- Dan Han (ORCID: https://orcid.org/0000-0002-5057-944X)
Institutions
- Union Hospital (HK)
- Xiangyang Central Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.3389/fonc.2025.1499701
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00